Omeros says international group receives EUR1.3M grant for brain injury study
Omeros announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded EUR1.3M in grant funding to study the benefits of inhibiting mannan-binding lectin-associated serine protease-2 and the lectin pathway in traumatic brain injury. Omeros' OMS721 is a human monoclonal antibody that inhibits MASP-2, which is the effector enzyme of the lectin pathway of the complement system. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2. The international consortium was awarded the grant by the Network of European Funding for Neuroscience Research, which is part of a European research area network funded by the European Commission. The consortium's project is entitled, "New therapeutic strategies in the treatment of traumatic brain injury by targeting the LEctin Activation Pathway of complement," and is focused on defining the contribution of lectin pathway activators and enzymes in driving post-traumatic brain injury and on assessing the therapeutic utility of MASP-2-blocking antibodies to reduce TBI-related morbidity and mortality in patients. The program also targets the development of biomarkers for use in TBI clinical trials. Omeros currently has an ongoing Phase 3 clinical program evaluating OMS721 in atypical hemolytic uremic syndrome as well as Phase 2 programs assessing the drug in hematopoietic stem cell transplant-associated thrombotic microangiopathy and in IgA nephropathy, membranous nephropathy, C3 glomerulopathy and lupus nephritis.